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Type 2 diabetes is a multifactorial disease with multiple underlying aetiologies. To address this 
heterogeneity a previous study clustered people with diabetes into five diabetes subtypes. The 
aim of the current study is to investigate the aetiology of these clusters by comparing their 
molecular signatures. In three independent cohorts, in total 15,940 individuals were clustered 
based on five clinical characteristics. In a subset, genetic- (N=12828), metabolomic- (N=2945), 
lipidomic- (N=2593) and proteomic (N=1170) data were obtained in plasma. In each datatype 
each cluster was compared with the other four clusters as the reference. The insulin resistant 
cluster showed the most distinct molecular signature, with higher BCAAs, DAG and TAG 
levels and aberrant protein levels in plasma enriched for proteins in the intracellular PI3K/Akt 
pathway. The obese cluster showed higher cytokines. A subset of the mild diabetes cluster with 
high HDL showed the most beneficial molecular profile with opposite effects to those seen in 
the insulin resistant cluster. This study showed that clustering people with type 2 diabetes can 
identify underlying molecular mechanisms related to pancreatic islets, liver, and adipose tissue 
metabolism. This provides novel biological insights into the diverse aetiological processes that 
would not be evident when type 2 diabetes is viewed as a homogeneous disease.   
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Type 2 diabetes is a multifactorial disease with multiple underlying aetiologies.(1; 2) In an 
attempt to address this heterogeneity, a recent study stratified people with any form of diabetes 
into five clusters based on six clinical variables, i.e. age, glutamate decarboxylase (GAD) 
antibodies, BMI, HbA1c, insulin resistance (HOMA2-IR) and β-cell function estimates 
(HOMA2-B).(3) Based on this work, we clustered and cross-validated individuals into five 
clusters in three large cohorts based on age, BMI, random or fasting c-peptide, HbA1c and 
HDL, largely reproducing the ANDIS clusters using more readily measured clinical 
variables.(4) 
 The original and subsequent papers have shown that people in different clusters had 
different risks for a number of diabetes related outcomes.(3; 5-7) The autoimmunity and insulin 
deficient cluster were defined by high HbA1c at diagnosis, had ketoacidosis and retinopathy(7) 
more often and progressed more rapidly onto insulin compared to the other clusters.(3) The 
insulin resistant cluster showed a higher frequency of non-alcoholic fatty liver disease and 
people in this group were at increased risk of developing chronic kidney disease.(3) The 
differences in progression and characteristics of the different clusters suggest that these groups 
represent different underlying aetiologies. For example, differences in genotype frequency 
across clusters based on candidate loci were observed and this was further illustrated in a 
follow-up study where it was shown that individuals in different clusters have differences in 
portioned polygenic risk scores for diabetes-related outcomes.(3; 8) 
A systematic deconvolution of the different etiological processes underlying the clusters 
is currently lacking. To address this, we investigate each cluster’s molecular signature using 
metabolomics, lipidomics, proteomics, and genomics to better understand the underlying 
aetiological processes representative of patients with diabetes in that cluster.  
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RESEARCH DESIGN AND METHODS 
 
Cohort descriptions 
Data from 15,940 individuals from three cohorts, DCS (Netherlands), GoDARTS (Scotland) 
and ANDIS (Sweden) were used in this cross-sectional study. Inclusion criteria for 
RHAPSODY were age of diagnosis was ≥35 years, clinical data available within 2 years after 
diagnosis, GAD negative, no missing data in one of the five for clustering used clinical 
measures and the presence of GWAS data. Individuals were clustered using k-means clustering 
based on five clinical characteristics age at sampling, BMI, HbA1c, HDL and C-peptide. Of 
note, C-peptide was included in the clustering as proxy of insulin resistance, while HDL has 
previously been recognized as risk factor for time to insulin requirement. Details on the cohorts 
and clustering have been described elsewhere.(4) Briefly, DCS is an open prospective cohort 
that started in 1998 comprised on over 14,000 individuals with type 2 diabetes from the 
northwest part of the Netherlands.(9) The Ethical Review Committee of the VU University 
Medical Center, Amsterdam has approved the study. People visit DCS annually as part of 
routine care. GoDARTS is a study comprising individuals with diabetes mellitus from the 
Tayside region of Scotland (N = 391,274; January 1996) that were added to the DARTS 
register.(10) The GoDARTS study was approved by the Tayside Medical Ethics Committee. 
Longitudinal retrospective and prospective anonymized data were collected, including data on 
prescribing, biochemistry, and clinical data. In ANDIS, people were recruited with incident 
diabetes within the Scania County, Sweden from January 2008 until November 2016.  
 
Molecular measures 
An overview of the sample selection procedure is given in Fig. S1a. Individuals were selected 
based on the shortest time between diagnosis date and sampling date without taking into 
account cluster assignment. Analysis of small charged molecule analytes (metabolomics, 
UHLPC-MS/MS) was performed in the largest set (N=2945), followed by lipidomics (N=2593, 
Lipotype lipidomics platform) and proteomics (N=1170, SomaScan® Platform- Somalogic). 
Of note, the smaller sets were selected from the larger set based upon the samples being 
collected closest to the time of diagnosis, so in the smallest set of 1170 GWAS, metabolomics, 
lipidomics and proteomics was available (Fig. S1a). Molecular measures were taken close to 
diagnosis (Table S2). Quality control was performed in a similar way for metabolomics, 
lipidomics and proteomics. A participant’s data was excluded if their profile was a strong outlier 
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based on principal components analysis and the data of the individual measurements was clearly 
distinct from the other samples. 
 
Genetic data 
In DCS, genetic data were generated using the Illumina HumanCoreExome array. In 
GoDARTS genetic data were generated using the Affymetrix Genome-Wide Human SNP 
Array 6.0 and the Illumina HumanOmniExpress Array. ANDIS was genotyped 
InfiniumCoreExome-24v1-1 BeadChip arrays (Illumina, San Diego, CA, USA), at Lund 
University Diabetes Centre, Malmö, Sweden. Samples were excluded for ambiguous gender, 
call rate < 95%, and any duplicate or related individuals (pi_hat ≥ 0.2). SNP were excluded for 
monomorphic SNPs, SNPs with MAF < 0.05, and SNPs with missingness rate > 0.05. 
Differences in diabetes-related genetic risk were based on 403 relatively independent diabetes 
associated SNPs identified in a recent large GWAS meta-analysis.(11) Genetic data were 
imputed using the Michigan Server against the reference panel Human Reference Consortium 
R1.1 using default settings, i.e. phasing with Eagle v2.3 and population of European 
descent.(12) SNPs with minor allele frequency below 5% were discarded from the analyses 
leaving 394 SNPs across the three studies.  
 
Metabolomics  
Fifteen small charged molecules were measured in plasma using targeted UHLPC-MS/MS 
(Steno Diabetes Center, Copenhagen, Denmark).(13) In DCS, 1267 individuals were included 
for metabolomics measurements. All passed QC and 1230 individuals overlapped with the 
cluster data. In GoDARTS, 898 individuals were included in the analysis, one failed QC and of 
the 897 remaining individuals, 894 overlapped with the cluster data. In ANDIS, 896 individuals 
were included in the analysis, four failed QC and of the 892 remaining samples, 821 overlapped 
with the cluster data.  
 
Lipidomics 
614 plasma lipids common to the three cohorts were determined using a QExactive mass 
spectrometer (Thermo Scientific) equipped with a TriVersa NanoMate ion source (Advion 
Biosciences) on the Lipotype lipidomics platform (Lipotype, Dresden, Germany).(14) Samples 
were divided into analytical batches of 84 samples each. Lipid identification was performed on 
unprocessed mass spectra files using LipotypeXplorer.(15) Only lipid identifications with a 
signal-to-noise ratio >5, and a signal intensity 5-fold higher than in corresponding blank 
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samples were considered for further data analysis. Batch correction was applied using eight 
reference samples per 96-well. Amounts were also corrected for analytical drift if the p-value 
of the slope was below 0.05 with an R2 greater than 0.75 and the relative drift was above 5%. 
In DCS, 900 individuals were included for lipidomics measurements, all passed QC and 877 
overlapped with the cluster data. In GoDARTS, 898 individuals were included in the analysis, 
one failed QC and of the 897 remaining samples, 894 overlapped with one of the clusters. In 
ANDIS, 896 individuals were included in the analysis, five failed QC and of the 891 remaining 
samples, 820 overlapped with one of the clusters. Lipid nomenclature is used as described 
previously and SwissLipids database identifiers are provided (Table S1).(16) After quality 
control 162 lipid species were used in this study. The median coefficient of subspecies variation 
of the 162 lipids used as accessed by reference samples was 9.49% across all three cohorts.  
 
Protein measurements 
Protein levels (1195 proteins) in plasma were measured on the SomaLogic SOMAscan platform 
(Boulder, Colorado, USA) in 600 individuals each for both DCS and GoDARTS. Individuals 
were removed if they were strong outliers based on a principal component analysis. In DCS, 
600 individuals were included for proteomics measurements, 11 failed QC and 573 overlapped 
with one of the cluster data. In GoDARTS, 600 individuals were included in the analysis, one 
failed QC and of the 599 remaining samples, 597 overlapped with one of the clusters. 
 
Statistical analysis 
Molecular data were log-transformed and z-scaled before analysis on a federated node system. 
Each of the cohorts’ data were stored on a local node using Opal, an open source data warehouse 
(Open Source Software for BioBanks, OBiBa). A central node responsible for federated node 
access, user administration and software deployment was set up at SIB. Clinical and molecular 
data were harmonized according to the CDISC Study Data Tabulation Model (www.cdisc.org).  
To identify molecular measures specific for a cluster, a generalized linear model was 
used to test each of the molecular measures in each cluster, where cluster i was compared 
against reference group j, where j was a combined group of the other clusters. Effect sizes 
represent change per log standard deviation of the tested molecular measure. Genetic data were 
not transformed and represent change in allele frequency. For example, cluster 1 was compared 
to clusters 2-5 combined, cluster 2 to clusters 1,3,4,5. Main results presented are based on an 
unadjusted model (log and z-scaled). Next, as an exploratory sensitivity analysis, models were 
adjusted for the extreme characteristic of a cluster to investigate whether the observed effect 
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was independent of the extreme characteristic. This was only done for those clusters that had 
extreme characteristics. Models were run on each of the cohorts separately and meta-analysed 
using the R-package meta.(17) Meta-analysed P-values were adjusted using the Benjamini-
Hochberg procedure and a false discovery rate-adjusted (FDR) P-value below 0.05 was 
considered significant. 
Partitioned polygenic risk scores (pPRSs) were obtained from Udler et al.(18). In each 
individual cohort, dosages of SNPs were multiplied with the scores for each cluster, which 
resulted in a risk score per individual for each of the five clusters beta cell (30 SNPs), proinsulin 
(7 SNPs), obesity (5 SNPs), lipodystrophy (20 SNPs) and liver (5 SNPs). Differences in pPRSs 
were tested with a linear model for one cluster with the other clusters as the reference group. 
Next, results from the three cohorts were meta-analysed using the metagen function from the 
meta package. P-values were Bonferroni adjusted and considered significant at Padj < 0.05.  
Pathway enrichment on the proteomics was performed based on KEGG pathways using 
the R-package of STRINGdb (1.24.0). The entire Somalogic set (1195 proteins) was used as 
the background set. P-values of enriched pathways were adjusted using the Benjamini-
Hochberg procedure and an FDR-adjusted P-value below 0.05 was considered significant. 
Effect sizes of proteins associated with eGFR and incident cardiovascular disease 
(CVD) were obtained from Yang et al. (2020).(19) Up- and downregulated proteins in each of 
the clusters (PFDR<0.05) were selected and compared to the from Yang et al. obtained 1) 
correlation coefficient of protein levels and eGFR and 2) hazard ratios from the Cox 
Proportional Hazard models for cardiovascular disease in non-CKD individuals.(19)  
Analyses were performed using R statistics (version 3.6.2). Figures were produced using 
the R-package ggplot2 (v3.3.0) and omicCircos (v1.22.0). 
 
Data and resource availability statement 
The datasets generated during and/or analysed during the current study are not publicly 





In this cross-sectional study, 15,940 individuals from three cohorts were included described 
previously.(4) As described, we reproduced the original ANDIS SIDD, SIRD and MOD 
clusters; and refined the MARD cluster into two, a subset with high HDL (MDH) and one 
without any particular defining features (MD). The characteristics of the clusters and those of 
the individuals used for molecular characterization (genetic data, metabolites, lipids, and 
proteins) are given in Table S2 and Table S3.  
 
Severe insulin-deficient cluster (SIDD) 
For SIDD, no differences were observed in allele frequency of known type 2 diabetes loci 
compared to the other clusters (Table S4), nor in the pPRS (Fig. S2). Two metabolites, tyrosine 
(Fig. 1a, Fig. 1b) and asymmetric/symmetric dimethylarginine (SDMA/ADMA, Fig. 1c, Table 
S5) were significantly lower in SIDD versus all other clusters. The effect sizes attenuated 
slightly after adjustment for the primary variable HbA1c that defined the SIDD cluster (Fig. 
S3b, Table S5). Of the lipids, eight were downregulated and one upregulated. Three of the 
eight downregulated lipids were of the sphingomyelin class, four lipids of the 
phosphatidylcholine class and one cholesterol ester (Fig. 2a, Table S6). The sole upregulated 
lipid was the cholesterol ester (CE 20:2;0). Seven out of nine lipids remained significant after 
adjustment (Fig. S3c, Table S6). Finally, eight proteins were differentially expressed with four 
up- and four downregulated (Fig. S4a-d), where the effect sizes remained similar after 
adjustment (Fig. S3d, Table S7). 
 
Severe insulin resistance cluster (SIRD) 
The SIRD cluster was characterized by a strong and distinct molecular signature of insulin 
resistance. The pPRS for beta-cell function and proinsulin (18) were decreased in the SIRD 
cluster relative to other clusters (beta cell, β[95%CI]=1.41[-2.21 – -0.62]; proinsulin, 
β[95%CI]=-0.28[-0.41 – -0.15], Fig. S2), indicating genetically higher beta-cell function in the 
SIRD group. Five diabetes-associated SNPs all showed a lower risk allele frequency. The top 
SNP (rs3802177-A) of SIRD mapped to the protective allele in SLC30A8 (Table S4, Table 1). 
In a sensitivity analysis, only the SLC30A8 variant remained significant after adjustment for C-
peptide (Fig. S3a, Table S4, Table 1). The SIRD cluster showed eight upregulated metabolites, 
including four amino acids, i.e. tyrosine, leucine, isoleucine, and phenylalanine (Fig. 1a, Fig. 
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S5a-b). Two were metabolites of the amino acid L-tryptophan, i.e. L-kynurenine and indoxyl 
sulphate. Adjustment for C-peptide attenuated the effect (Fig. S3b, Table S5). 
Eighty-nine lipids were changed in SIRD, with 45 (50.6%) upregulated and 44 
downregulated (49.4%, Fig. 2a). Of the 45 upregulated lipids, 43 were in the di- and 
triacylglycerol class with TAG 51:3;0 as the strongest associating lipid (Fig. 2b, Table S6), 
while the remaining two upregulated lipids were phosphatidylcholines containing the omega-3 
fatty acid docosahexaenoic acid (22:6;0, PC 18:0;0_22:6;0, PC 16:0;0_22:6;0). Of the 44 
downregulated lipids, the most represented were the phosphatidylcholines class (27 lipids, 
61.4%), especially with the ether phosphatidylcholines (38.6%), with PC O-16:0;0/18:1;0 being 
the strongest downregulated lipid (Fig. 2a, Fig. 2c, Table S6). Also, most ether 
phosphatidylethanolamines are (four lipids, 9.1%) and sphingomyelin species were 
downregulated (7 lipids, 15.9%). The changes in lipids seemed to be dependent on the high C-
peptide levels with effect sizes of DAG and TAGs close to zero after adjustment for the latter 
(Fig. S3c, Table S6).  
Out of the 1195 plasma proteins investigated, 367 proteins were differentially 
expressed, with 158 proteins downregulated and 209 upregulated. Several top proteins were 
upregulated independent of C-peptide levels, including two metalloproteinases, matrix 
metalloproteinase-7 (MMP-7) and Macrophage metalloelastase (MMP-12), and MIC-1 (Table 
S7). Metalloproteinases are associated with multiple physiological processes, but also with 
atherosclerosis and diabetes-related nephropathy.(20; 21) MIC-1 (GDF-15) is known to be 
associated with insulin resistance.(22) The identified proteins showed a strong enrichment in 
pathways, including Cytokine-cytokine receptor interaction (50 proteins, PFDR=8.69·10-56), 
Chemokine signalling pathway (26 proteins, PFDR=1.81·10-34), Axon guidance (26 proteins, 
PFDR=3.55·10-34) and PI3K-Akt signalling pathway (29 proteins, PFDR=1.05·10-29). There was a 
significant reduction in 3-phosphoinositide-dependent protein kinase-1 (PDPK1, Fig. 3a, Fig. 
3c), which, when activated by insulin, activates Akt/PKB and increases glucose uptake via 
GLUT4.(23) Plasma Akt itself was also decreased in SIRD (Fig. 3a). Insulin tended to be higher 
in SIRD although not significant (Fig. 3b), while the insulin receptor was significantly 
upregulated (Fig. 3a). In the downstream signalling cascade of the PI3K-Akt pathway, PDPK1 
(Fig. 3c), RAC1, AMPK, HSP90, 14-3-3 and p53 were differentially expressed (Fig. S5c-i). Of 
note, the proteins associated with SIRD were only modestly driven by C-peptide levels (Fig. 
S3d). 
Next, we overlapped identified proteins with those previously associated with eGFR 
and incident CVD.(19) Proteins upregulated in SIRD, were previously associated with lower 
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eGFR levels, including Cystatin C (ρ= -0.74, P= 1.12·10-163), Tumor Necrosis Factor receptor 
superfamily member 1A (TNF sR-I, ρ= -0.65, P= 2.51·10-114) and Neuroblastoma suppressor 
of tumorigenicity 1 (DAN, ρ= -0.64, P= 2.29·10-109, Fig. S7a). Conversely, proteins positively 
associated eGFR were downregulated including Epidermal growth factor receptor (ERBB1, ρ= 
0.44, P= 1.96·10-46) and Alpha-2-antiplasmin (ρ= 0.41, P= 1.42·10-38). For incident 
cardiovascular disease (CVD), Angiopoietin-2 (HR=1.66, P=2.20·10-16) and MMP-12 
(HR=1.65, P=2.20·10-16) were upregulated risk factors in SIRD, while ERBB1 (HR=0.59, 
P=2.20·10-16) was protective for CVD and downregulated in SIRD (Fig S7b). 
 
Mild Obesity-related Diabetes (MOD) 
In MOD, the pPRS for obesity was significantly higher (β[95%CI]=0.51[0.34 – 0.68], Fig. S2) 
compared to other clusters. Individual diabetes-associated risk alleles associated with high BMI 
were also more frequent in MOD, that is FTO (rs1421085-C) and the MC4R locus (rs523288-
T, Table S4, Table 1). Of note, both loci are also in the pPRS, although using different SNPs 
in LD. Naturally, adjustment for BMI attenuated the effect size for both SNPs (Fig. S3a, Table 
S4). 
Isoleucine was the sole metabolite that was differentially upregulated in MOD (Fig. 1a, 
Fig. S4a, Table S5), and this difference was completely eliminated after adjustment for BMI. 
The lipid profile of the MOD cluster was largely similar to the SIRD cluster (Fig. 2a, Table 
S6). That is, in MOD, acyl phosphatidylethanolamine species were upregulated, but not the 
ether phosphatidylethanolamines. Cholesterol esters and phosphatidylcholine species 
containing the omega-3 fatty acids eicosapentaenoic acid (20:5;0) and docosahexaenoic acid 
(22:6;0) were downregulated, while these were upregulated or not significantly changed in the 
SIRD cluster. However, cholesterol esters and phosphatidylcholine species containing 20:3;0 
fatty acids are upregulated in MOD, while downregulated or not significantly changed in the 
SIRD cluster. In total 61 lipids were affected of which 40 were upregulated. Amongst these the 
diacylglycerols (15%) and triacylglycerols (57.5%) were strongly enriched. Of the 21 
downregulated lipids, the majority were phosphatidylcholines (61.9%). The effect size for 
diacylglycerol and triacylglycerol changes were strongly reduced after adjustment for BMI 
(Fig. S3c, Table S6). Interestingly, the largest effect size was seen in the TAGs with the lowest 
number of acyl chain carbons and double bonds (Fig. S6a-b), while the TAGs with more acyl 
chain carbons and double bonds were not significantly altered in MOD. In a previous study, 
saturated or monounsaturated TAGs were associated with an increased diabetes risk, including 
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TAG 46:1, TAG 48:0 and TAG 48:1 that were also significantly upregulated in the MOD 
cluster.(24)  
Of the 1195 proteins, 261 were differentially expressed in MOD with the majority 
downregulated (158 proteins, 60.5%, Table S7). After adjustment for BMI, several remained 
significant, although their effect sizes were attenuated, including NCAM-120, DKK3 and 
CRDL1 (Fig. S3d, Table S7). DKK3 has been associated with increased adipogenesis in fat 
cells.(25) CRDL1 has been shown to be predictive of beta-cell function.(26) The role of 
NCAM-120 is largely unclear. The strongest enrichment was found for Cytokine-cytokine 
receptor interaction with 38 proteins (42.7%, PFDR=2.08·10-43) overlapping (Fig. S8). The 
strongest upregulated proteins in this pathway were leptin (Fig. S4b), growth hormone receptor 
and Interleukin-1 receptor antagonist protein, while Interleukin-1 receptor type 1(IL-1 sRi) was 
downregulated. Adjustment for BMI influenced the effect size of several proteins, including 
leptin, FABP and CRP (Fig. S3d, Table S7). Finally, upregulated proteins identified in MOD 
were generally positively associated with eGFR and protective for CVD, including the growth 
hormone receptor (HR=0.62, P=2.20·10-16, Fig. S7). 
 
Mild diabetes with high HDL 
The MDH cluster showed a higher GRS relative to the other clusters for beta-cell function 
(β[95%CI]=0.61[0.33-0.38], Fig. S2). Among the diabetes-associated SNPs, a lower risk allele 
frequency was observed for a SNP near LPL (rs10096633-T, Table S4, Table S1). With respect 
to metabolite-, lipid- and peptide levels the MDH cluster showed opposite effects compared to 
the SIRD and MOD cluster. The amino acids that were upregulated in SIRD were generally 
downregulated in MDH (Fig. 1a, Table S5). Only the difference in isoleucine level was 
significant and phenylalanine borderline insignificant. In addition, taurine was significantly 
upregulated in MDH. After adjustment for HDL the effect sizes strongly attenuated (Fig. S3b, 
Table S5).  
Out of the 162 lipids, 135 lipids were affected in MDH, with 52 downregulated and 83 
upregulated (Table S6). Opposite to SIRD and MOD, diacylglycerols (13.5%), triacylglycerols 
(73.1%) and acyl phosphatidylethanolamines (9.6%) were downregulated in MDH, while 
phosphatidylcholines (65.1%) were upregulated, especially the ether phosphatidylcholines (PC 
O-, 25.6%, Table S6). The TAGs with a smaller number of acyl chain carbons and double 
bonds showed the lowest protein levels versus the other clusters, while the differences 
attenuated with increasing number of acyl chain carbons and double bonds (Fig. S6a-b). In 
addition, upregulation was seen for cholesterol esters (13.3%), sphingomyelins (10.8%) and all 
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ether phosphatidylethanolamines (9.6%), which point in the opposite direction in the SIRD 
cluster (Table S6). Adjustment for HDL strongly decreased the effect size for diacylglycerols 
and triacylglycerols (Fig. S3c, Table S6). 
Out of the 1195 proteins, 270 proteins were differentially expressed in the MDH cluster 
(119 down, 151 upregulated). The effect size of the proteins changed very modestly after 
adjustment for HDL (Fig. S3d). The peptide profile of the MDH cluster was opposite of that of 
MOD (Fig. S9, r=-0.82). As such among the top proteins similar proteins were identified such 
as CRDL1 that remained significant after adjustment for HDL. The pathway enrichment 
resembled that of SIRD and MOD, with enrichment for Cytokine-cytokine receptor interaction 
(31 proteins, PFDR=7.04·10-32), Pathways in cancer (22 proteins, PFDR=2.35·10-24) and PI3K-
Akt signalling pathway (22 proteins, PFDR=5.56·10-23). In the latter, growth hormone receptor 
was downregulated, as well as insulin (Fig. 3b, Table S7). Effect sizes were generally not solely 
driven by increased HDL levels (Fig. S3d, Table S7). MDH-associated proteins in relation to 
eGFR showed a similar pattern to that of SIRD (Fig. S7a-b), with proteins associated with 
lower eGFR being upregulated as well as proteins associated with higher risk for CVD, the 




The MD cluster was generally less well-defined, with only one significant SNP and no 
significant GRSs, lipids or metabolites. There was a higher risk allele frequency (C-allele) in 
MD – opposite to that of MDH – compared to the other clusters near the LPL gene (rs10096633-
T, Table S4). In contrast to the few signals for lipids or metabolites, 354 proteins were 
differentially expressed in the MD cluster, with the majority downregulated (209 proteins, 
59.0%). Enrichment was found for Axon guidance (20 proteins, PFDR=1.12·10-30), Cytokine-
cytokine receptor interaction (25 proteins, PFDR=3.48·10-25), PI3K-Akt signalling pathway (21 
proteins, PFDR=4.28·10-23). While similar pathways were found to be enriched compared to the 
SIRD cluster the effect sizes were correlated but reversed (r=-0.88, Fig. S9). In line with this, 
insulin and its receptor were significantly downregulated in MD. Finally, in MD upregulated 







Based on five clinical variables, people with type 2 diabetes from three large European cohorts 
were assigned to five separate clusters. The molecular phenotyping of the clusters revealed that, 
in addition to differences in clinical characteristics, there were also profound differences in 
underlying molecular profiles which related to pancreatic islet biology (in SIDD), liver (in 
SIRD) and adipose tissue metabolism (in MOD and MDH).   
The SIRD cluster was characterized by a molecular profile that fits with insulin 
resistance, i.e. upregulation of DAGs, BCAAs and insulin and downregulation of PI3K-Akt 
pathway-related proteins and phosphatidylcholines. The MOD cluster showed overlap with the 
SIRD cluster, but with a more pronounced molecular profile of obesity. Individuals in the MDH 
cluster showed the opposite effect of SIRD and MOD with, relative to the other clusters, low 
levels of TAG, DAG and BCAAs, but higher levels of ether phosphatidylcholines and 
phosphatidylethanolamines, sphingomyelins, and cholesterol esters. The results were in part, 
but not fully, driven by the identifying characteristic of the cluster, except for SIDD which 
showed consistent results after adjustment for HbA1c. For example, effect sizes of TAGs and 
DAGs in SIRD and MDH were influenced by adjustment for C-peptide and HDL, respectively. 
The lower frequency of diabetes-associated risk alleles could be explained by the fact that most 
diabetes SNPs are associated with reduced insulin-secretion. People in the SIRD cluster do not 
have diabetes because of lower insulin secretion but because of high insulin resistance (and 
consequent greater beta-cell function).  
The SIDD cluster was characterized by greater insulin sensitivity and lower beta-cell 
function than the other clusters based on the clinical characteristics. SIDD is characterized by 
low tyrosine levels and (a)symmetric dimethylargine, CE 16:1;0, PC O-34;1 and PC O-34;2, 
compared to the other clusters; higher levels of these metabolites and lipids have been 
associated with higher type 2 diabetes risk.(27-30) Higher CE 16:1;0 has also been associated 
with higher fasting plasma glucose (FPG) and 2-hour post-loading glucose (2h-PLG).(31) 
Moreover, in SIDD, CRP was downregulated and this is in line with a previous report that CRP 
levels are generally higher in those with insulin resistance and not low secretion.(32) 
The SIRD – and to some extent the MOD cluster – showed opposing metabolite, lipid 
and protein profiles compared to the MDH cluster (Fig. 4). The SIRD cluster was characterized 
by a molecular signature compatible with insulin resistance inside cells. In SIRD, the frequency 
of protective alleles was higher for HOMA-B-associated variants. Evidence was found for 
downregulation of insulin-mediated glucose uptake across the different omics levels, where for 
example higher levels of BCAA and DAG/TAG were observed. BCAAs have been shown to 
16 
 
be risk factors for developing incident type 2 diabetes in observational studies; their causal role 
has also been suggested.(33) Both BCAAs and DAG inhibit insulin receptor substrate 1 
(IRS1).(34) DAGs activate PKC isoforms which inhibit PI3K activation by phosphorylating 
the inhibitory serine 307 of IRS1 instead of tyrosine.(34; 35) BCAAs target the intramuscular 
mammalian target of rapamycin/ribosomal protein S6 kinase beta-1 (mTOR/p70S6K) 
signalling pathway as shown in in vitro and rodent in vivo studies that also inhibits the PI3K/Akt 
pathway via IRS1 and IRS2 depending on the cell type.(34) Inhibition of PI3K/Akt reduces the 
GLUT4 translocation. In SIRD multiple proteins were downregulated in PI3K/Akt and the 
GLUT4 translocation pathway, including Akt, PDPK1, RAC1, while insulin was strongly 
upregulated.(36; 37) Furthermore, upregulation was seen in three ephrin family members 
(Ephrin A2,A2,A5). Inhibition of the ephrin receptors has been shown to enhance glucose-
stimulated insulin secretion in mice.(38) Although these results might suggest changes in the 
insulin or glucose responsiveness of relevant metabolic tissues (e.g. muscle, liver or adipose), 
proteins were measured in plasma in the current study and, as such, are unlikely to reflect 
changes in intracellular signalling. Future studies will be needed to determine the tissue(s) of 
origin of these biomarkers and the mechanisms through which they are released. For example, 
tissue-specific knock-out of proteins identified in plasma in cell lines or model organisms might 
provide insight into both the role and tissue of origin. The higher BMI in individuals in the 
MOD cluster was in line with the higher allele frequency of variants associated with a higher 
BMI, i.e. variants near FTO and MC4R. Interestingly also variants near TM6SF2 were 
associated with this cluster. TM6SF2 is known to be associated with NASH.(39) The metabolic 
and lipid profile of MOD resembled that of SIRD. An interesting observation was that the 
number of acyl chain carbons and double bonds was associated with the effect size in some 
clusters in particular MOD and MDH. In MOD lipids with a higher number of acyl chain 
carbons and double bonds the effect size was much lower compared to those with lower 
numbers. These findings are in line with a previous publication that showed that TAGs with a 
lower number of acyl chain carbons and double bonds are elevated in T2D cases versus 
controls.(24) In addition, lipids that were associated with increased diabetes risk were generally 
saturated or monounsaturated fatty acids.(24) MOD was further characterized by upregulation 
of leptin, growth hormone receptor and multiple interleukins and IL-1Ra. People with a high 
BMI have high levels of leptin, which may be a marker of leptin resistance.(40) IL-1Ra is 
negatively correlated with quantitative insulin sensitivity check index (QUICKI), where higher 
levels associate with higher insulin resistance.(32)  
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The MDH cluster was the cluster with the most beneficial profile and had a molecular 
signature of insulin sensitivity. This cluster had high HDL levels, low BCAA levels, low DAGs, 
and high levels of ether phosphatidylcholines relative to the other clusters (Fig. 4). Regarding 
the peptide level, the effects were opposite of the MOD cluster. MDH cluster displayed high 
levels of anti-inflammatory fatty acids which have been associated with improved insulin 
sensitivity in animal studies(41-43). 
In the study by Ahlqvist et al.(3) the SIRD cluster was associated with poorer renal 
function. In the current study we compare the identified proteins to proteins previously 
associated with eGFR levels and CVD-risk.(19) We show that proteins identified in the current 
study upregulated in the SIRD and MDH cluster are generally associated with lower eGFR 
levels and higher risk for CVD and conversely those downregulated in these two clusters are 
associated with higher eGFR levels and lower CVD risk. An explanation may be that 
individuals in the SIRD and MDH cluster are generally older compared to the other three 
clusters. These results also further confirm the added value of adding HDL to the clustering as 
the MOD and MD cluster were much more alike than MD and MDH. The proteins upregulated 
in the MD and MOD cluster were associated with higher eGFR levels and lower CVD risk. 
The strengths of the current study include the large number of individuals, the use of 
multiple cohorts and the use of multiple molecular layers to characterise the clusters. A 
limitation is that the identified markers are measured in plasma and as such they cannot be 
directly linked to specific metabolic tissues. Second, whilst we adjusted models for the 
characteristic of that cluster to identify markers that were not simply proxies of the clinical 
features that defined the cluster we cannot estimate whether we were able to fully adjust for 
that characteristic. Third, in the current study we compared the levels of molecular measures 
between individuals with type 2 diabetes and not relative to healthy controls. We can therefore 
not infer which cluster would be most close to the general population. Fourth, we use a validated 
quantitative method to measure metabolites that have previously been linked to diabetes, but 
the limitation of this targeted method is that  other metabolites are not measured. As such, we 
may have missed metabolites with differential levels across clusters. As such, we may have 
missed metabolites with differential levels across clusters. Finally, the cohorts used are mainly 







In the current study, clusters were identified in three cohorts, based on five different clinical 
characteristics. The underlying molecular signatures of each cluster were markedly different 
(Fig. 4) suggesting different underlying etiopathological processes. As expected, the identified 
molecular signatures reflected the underlying phenotype to some extent, but often remained 
associated after adjustment. Importantly, our study provides important new granularity on the 
likely molecular processes involved in diabetes pathology in each of the diabetes subgroups.  
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Table 1 Significant SNPs in each of the clusters 
Variant 
 
Cluster Chr Position Gene Risk allele REF ALT 
Risk AF 
in cluster Effect Lower Upper P-value I2 Heterogeneity  
rs3802177 SIRD 8 118185025 SLC30A8 G G A ↓ 0.07 0.04 0.10 2.19·10-5 0.09 0.14  
rs10811660 SIRD 9 22134068 CDKN2A/B G G A ↓ 0.05 0.02 0.07 8.72·10-5 0.00 0.59  
rs7903146 SIRD 10 114758349 TCF7L2 T C T ↓ -0.10 -0.15 -0.05 1.59·10-4 0.62 0.02  
rs11708067 SIRD 3 123065778 ADCY5 A A G ↓ 0.05 0.02 0.08 3.76·10-4 0.00 0.31  
rs243024 SIRD 2 60583665 BCL11A A G A ↓ -0.06 -0.10 -0.03 6.12·10-4 0.10 0.14  
rs1421085 MOD 16 53800954 FTO C T C ↑ 0.06 0.03 0.09 3.99·10-5 0.00 0.53  
rs10893829 MOD 11 128042575 ETS1 T T C ↓ 0.04 0.02 0.06 6.62·10-5 0.00 0.35  
rs523288 MOD 18 57848369 MC4R T A T ↑ 0.05 0.02 0.08 1.54·10-4 0.00 0.23  
rs8107974 MOD 19 19388500 TM6SF2 T A T ↓ -0.04 -0.06 -0.02 2.60·10-4 0.32 0.09  
rs10096633 MD 8 19830921 LPL C C T ↑ -0.04 -0.05 -0.02 7.60·10-5 0.00 0.57  





Figure 1 Metabolite levels in the five clusters. a. Change in metabolites levels in each of the 
clusters versus all others. Colours represent effect size in log SD, with red upregulation and 
blue downregulation. SDMA/ADMA, Symmetric dimethylarginine/Asymmetric 
dimethylarginine; TCA, Taurocholic acid; GUDCA, Glycoursodeoxycholic acid. b. Levels of 
tyrosine in DCS, GoDARTS and ANDIS. SIDD and SIRD PFDR < 0.05. c. Levels of (a) 
symmetric dimethylarginine. SIDD and SIRD PFDR ≤ 0.05. Dots represent the median, the 
vertical line the interquartile range. SIDD, Severe Insulin-Deficit Diabetes; SIRD, Severe 
Insulin-Resistant Diabetes cluster; MOD, Mild Obesity-related Diabetes; MD, Mild diabetes; 
MDH, Mild diabetes with high HDL. 
 
Figure 2. Lipid levels in the five clusters. a. Change in lipid levels in each of the clusters 
versus all others. Colours represent effect size in log SD, with red upregulation and blue 
downregulation b. Levels of TAG 51:3;0 in DCS, GoDARTS and ANDIS. SIRD, MOD and 
MDH PFDR ≤ 0.05. c. Levels of PC O-16:0;0/18:1;0. SIRD, MOD and MDH PFDR ≤ 0.05. Dots 
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represent the median, the vertical line the interquartile range. SIDD, Severe Insulin-Deficit 
Diabetes; SIRD, Severe Insulin-Resistant Diabetes cluster; MOD, Mild Obesity-related 
Diabetes; MD, Mild diabetes; MDH, Mild diabetes with high HDL. 
 
Figure 3 Proteins in the PI3K/Akt pathway in the five clusters. a. Effect sizes of proteins 
in the PI3K/Akt pathway (PFDR=1.05·10-29) with red upregulation in the cluster versus all 
others and blue downregulation. Bars on the left indicate whether proteins are statistically 
significant in a specific cluster. Dots represent the median, the vertical line the interquartile 
range. b. Levels of insulin in DCS, GoDARTS and ANDIS. MDH PFDR ≤ 0.05. c. Levels of 
PDPK1. Dots represent the median, the vertical line the interquartile range. SIRD PFDR ≤ 0.05.  
 
Figure 4 Schematic overview of the results in the current study. BCAAs, DAGs, TAGs, 
PE were upregulated in SIRD and to a lesser extend MOD, while being downregulated in 
MDH. PE O-, sphingomyelins and proteins associated with the PI3K/Akt pathway were 
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downregulated in SIRD. In MOD proteins were found upregulated that have been associated 
with cytokine-cytokine interaction. SIDD, Severe Insulin-Deficit Diabetes; SIRD, Severe 
Insulin-Resistant Diabetes cluster; MOD, Mild Obesity-related Diabetes; MD, Mild diabetes; 
MDH, Mild diabetes with high HDL. 
